Lanean...
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiratero...
Gorde:
| Argitaratua izan da: | Int J Cancer |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6099279/ https://ncbi.nlm.nih.gov/pubmed/29574703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31397 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|